What is a typical hospital management strategy for non-ICU diabetic patients with hyperglycemia?

Master the HCC1 Glucose Regulation Test with targeted questions and explanations. Enhance your preparation and boost your confidence for the exam!

Multiple Choice

What is a typical hospital management strategy for non-ICU diabetic patients with hyperglycemia?

Explanation:
In non-ICU inpatients, the goal is to keep blood glucose in a safe, steady range by mimicking normal insulin patterns: a basal insulin to provide ongoing coverage and rapid-acting (bolus) insulin around meals to handle post-meal spikes, with adjustments as needed. The typical target range for most non-critically ill patients is about 140–180 mg/dL, which balances the risks of hyperglycemia with the danger of hypoglycemia during illness. Relying on an IV insulin drip without monitoring is reserved for ICU-level care; starting metformin alone isn’t appropriate in acute illness due to potential kidney issues and lactic acidosis risk; and waiting for glucose to exceed 400 mg/dL before starting insulin would let hyperglycemia go untreated. A plan that uses sliding-scale insulin in combination with basal-bolus coverage and careful monitoring provides steady control and the ability to correct highs without excessive fluctuations.

In non-ICU inpatients, the goal is to keep blood glucose in a safe, steady range by mimicking normal insulin patterns: a basal insulin to provide ongoing coverage and rapid-acting (bolus) insulin around meals to handle post-meal spikes, with adjustments as needed. The typical target range for most non-critically ill patients is about 140–180 mg/dL, which balances the risks of hyperglycemia with the danger of hypoglycemia during illness. Relying on an IV insulin drip without monitoring is reserved for ICU-level care; starting metformin alone isn’t appropriate in acute illness due to potential kidney issues and lactic acidosis risk; and waiting for glucose to exceed 400 mg/dL before starting insulin would let hyperglycemia go untreated. A plan that uses sliding-scale insulin in combination with basal-bolus coverage and careful monitoring provides steady control and the ability to correct highs without excessive fluctuations.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy